Chongqing Huapont Shengchem Pharmaceutical is an API manufacturer based in China. It holds 16 active US drug master files across a filed portfolio of 16 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 21 June 2024 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3030151600 |
| China, China | 3008481320 |
| Molecule | Regulators | Docs |
|---|---|---|
| Ruxolitinib | SFDA (Saudi Arabia), US FDA | 3 |
| Calcipotriol | US FDA | 2 |
| Benidipine | US FDA | 1 |
| Bilastine | US FDA | 1 |
| Calcium | US FDA | 1 |
| Crizotinib | US FDA | 1 |
| Enzalutamide | US FDA | 1 |
| Finerenone | US FDA | 1 |
| Fulvestrant | US FDA | 1 |
| Isoniazid | US FDA | 1 |
| Isotretinoin | SFDA (Saudi Arabia) | 1 |
| Nintedanib | US FDA | 1 |
| Perfluorohexyloctane | US FDA | 1 |
| Posaconazole | US FDA | 1 |
| Roflumilast | SFDA (Saudi Arabia) | 1 |
| Upadacitinib | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
Choose your molecules and target markets. Chongqing Huapont Shengchem Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free